Interfyl® Human Connective Tissue Matrix (CTM)



Interfyl®
Human Connective Tissue Matrix
A Celularity Innovation

Arthrex®

Interfyl® Connective Tissue Matrix (CTM)

Interfyl® is a decellularized human placental CTM to be used for the replacement or supplementation of damaged or inadequate integumental tissue. Unlike standard therapies, Interfyl CTM provides a native extracellular matrix for cell attachment, as shown in in vitro data.[1]

What Makes Interfyl Connective Tissue Unique?

- **Does Not Contain Amnion:** Interfyl connective tissue contains only CTM.
- **The Chorion Difference:** The only CTM filler derived exclusively from the chorionic plate of the human placenta.
- **Minimally Processed:** Minimal processing helps retain the fundamental structure and functional characteristics of native connective tissue.



Advantages

- In vitro studies indicate that Interfyl connective tissue matrix supports cellular functions in soft-tissue management[1]
- Human monocytes on CTM show good adherence and viability[1]



Figure 1. Monocyte viability on CTM and TCP. More monocytes adhered to CTM than to TCP at 24 hours.[1]



Figure 2. The viability of monocytes on CTM and TCP was measured using alamarBlue™ assay at days 1 and 3. There were significantly more monocytes on CTM than on TCP at both time points.[1]

Features and Benefits

- **Highly Adaptable:** Suited for a variety of surgical applications where there is a need to replace or supplement damaged or inadequate integumental tissue.
- **Can Fill Irregular Spaces:** Interfyl matrix's flowable form enables it to conform to challenging contours and fill irregular spaces or soft-tissue deficits resulting from trauma or surgery.
- **No Residual Growth Factors, Cytokines, Cells, Cell Debris, or DNA:** Serves as a cell-friendly structure for cell attachment. Cell attachment is a natural stimulus for the orderly release of growth factors to support the body's natural healing process.

Interfyl® CTM provided a natural, native extracellular matrix (ECM) that supported efficient transition from M1 macrophages (pro-inflammatory) to M2 macrophages (which support healing and remodeling).[1]

Pro-inflammatory Factors

Demonstrated a steady **decrease** of pro-inflammatory factors over six days.

Interleukin 1 beta (IL-1β)



IL-8



*GM-CSF = granulocyte-macrophage colony-stimulating factor

Anti-inflammatory Factors

Demonstrated a steady **increase** of anti-inflammatory factors over six days.

CCL22



CCL18



Development of Tubular Branches

Interfyl CTM supports tube formation by endothelial cells, a precursor to angiogenesis, which enables blood flow and revascularization of the damaged tissue.[1]





Ordering Information

Product Description	Item Number
Interfyl® Tissue Matrix, 50 mg particulate	**HCTM050**
Interfyl Tissue Matrix, 100 mg particulate	**HCTM100**
Interfyl Tissue Matrix, 0.3 mL flowable	**HCTM030**
Interfyl Tissue Matrix, 0.6 mL flowable	**HCTM060**
Interfyl Tissue Matrix, 1 mL flowable	**HCTM010**
Interfyl Tissue Matrix, 1.5 mL flowable	**HCTM015**

Products advertised in this brochure / surgical technique guide may not be available in all countries. For information on availability, please contact Arthrex Customer Service or your local Arthrex representative.

For product information, product complaints, or adverse reaction reporting, call (844)-963-2273.

References

1. Pashuck ET, Mao Y, Kim K, John K, Smiell J, Bhatia MB. A human placenta-derived decellularized connective tissue matrix (CTM) supports cellular functions involved in wound healing processes. Paper presented at: Symposium on Advanced Wound Care; October 7-9, 2016. Las Vegas, NV.

Indications for Use

- **For surgical indications:** Interfyl is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to, treatment of soft tissue voids, correction of soft tissue defects, soft tissue augmentation during repair of dehisced or complicated surgical closures and repair of small surgical defects resulting from either medical or surgical conditions including those with exposed vital structures (bone, tendon, ligament, or nerve).
- **For wound indications:** Interfyl is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to: augmentation of deficient/inadequate soft tissue and treatment of deep dermal wounds; surgical wounds; soft tissue voids as a result of tunneling wounds, fistula tracts, or dermal undermining-including those with exposed vital structures (bone, tendon, ligament, or nerve).

Contraindications, Warnings, and Precautions

- If a recipient had an adverse reaction related to previous use of Interfyl, do not re-apply.
- Do not use Interfyl for intravenous, intra-arterial, intra-ocular, or intrathecal applications.
- Interfyl must be used prior to the expiration date on the product pouch. Once opened, Interfyl must be used within two hours or discarded per institutional procedures. The contents are sterile if the vial/syringe (container) is unopened and undamaged. Do not sterilize.
- For product information, product complaints, or adverse reaction reporting, call (844)-963-2273.
- Please refer to the Interfyl Package Insert for complete product information.

celularity®

Interfyl® is a registered trademark of Celularity Inc.
For product information or adverse reaction reporting, call (844) 963-2273.

Please refer to package insert for complete product information.

This description of technique is provided as an educational tool and clinical aid to assist properly licensed medical professionals in the usage of specific Arthrex products. As part of this professional usage, the medical professional must use their professional judgment in making any final determinations in product usage and technique. In doing so, the medical professional should rely on their own training and experience and should conduct a thorough review of pertinent medical literature and the product's directions for use. Postoperative management is patient-specific and dependent on the treating professional's assessment. Individual results will vary and not all patients will experience the same postoperative activity level or outcomes.

View U.S. patent information at www.arthrex.com/corporate/virtual-patent-marking

arthrex.com

Arthrex®